Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
68 hedge funds and large institutions have $118M invested in Adverum Biotechnologies in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 13 closing their positions.
1,280% more call options, than puts
Call options by funds: $414K | Put options by funds: $30K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
11% more funds holding
Funds holding: 61 → 68 (+7)
5.35% more ownership
Funds ownership: 80.72% → 86.07% (+5.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
50% less capital invested
Capital invested by funds: $237M → $118M (-$119M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$10.5M |
| 2 |
BlackRock
New York
|
+$10.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$10.1M |
| 4 |
Goldman Sachs
New York
|
+$3.69M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.1M |
| 2 |
CC
Commodore Capital
New York
|
-$9.29M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$6.21M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.2M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$4.12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Balyasny Asset Management
Chicago,
Illinois
| – | -$201K | -14,198 | Closed |
|
|
PAS
77
Point72 Asia (Singapore)
Singapore
| – | -$131K | -9,276 | Closed |
|
|
CSS
78
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$120K | -8,483 | Closed |
|
79
Acadian Asset Management
Boston,
Massachusetts
| – | -$41K | -2,902 | Closed |
|
80
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$37 | -2,586 | Closed |
|
81
Lazard Asset Management
New York
| – | -$6.08K | -654 | -93% |
|
ADVM Hedge Fund Activity: Q2 2024 in Review
68 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2024, worth a combined $118M — down 50% from $237M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ADVM positions and 13 closed out — a net gain of 7 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was BML Capital Management, adding an estimated $10.5M. The largest seller was Logos Global Management, cutting an estimated $10.1M.
- 68 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2024, up from 61 in Q1 2024.
- Funds reported $118M of Adverum Biotechnologies stock for Q2 2024, down 50% quarter-over-quarter.
- 20 funds opened new Adverum Biotechnologies positions in Q2 2024 and 13 closed out, a net change of +7 holders.
- The largest Adverum Biotechnologies buyer in Q2 2024 was BML Capital Management, an estimated $10.5M added.
- The largest Adverum Biotechnologies seller in Q2 2024 was Logos Global Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2024.